These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33190022)

  • 21. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
    J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.
    Suzuki Y; Sano H; Mochizuki L; Honkura N; Urano T
    Blood Adv; 2020 Nov; 4(21):5501-5511. PubMed ID: 33166409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
    Morishima Y; Kamisato C; Honda Y
    J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB; Wang W; Bajzar L; Nesheim ME
    J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro.
    Tanaka K; Tawara S; Tsuruta K; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):859-866. PubMed ID: 29683037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
    Foley JH; Nesheim ME; Rivard GE; Brummel-Ziedins KE
    Haemophilia; 2012 May; 18(3):e316-22. PubMed ID: 21933309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin.
    Tawara S; Sakai T; Matsuzaki O
    Thromb Res; 2016 Nov; 147():72-79. PubMed ID: 27693845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM; Taylor FB; Peer G; Bajzar L
    Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
    Toh CH
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB
    BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
    Wu C; Kim PY; Swystun LL; Liaw PC; Weitz JI
    J Thromb Haemost; 2016 Feb; 14(2):366-74. PubMed ID: 26663133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
    Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
    Morishima Y; Kamisato C; Honda Y
    Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
    Morser J; Gabazza EC; Myles T; Leung LL
    J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.